Dr. Andreadis on Response to CAR T-Cell Therapy

Video

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

Response to CAR T-cell therapy may not be immediate, explains Andreadis, noting that a delayed partial response does not mean that the therapy failed. Based on the data surrounding axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah), physicians know that patients may take a long time to respond to CAR T cells.

Data have shown that patients may take up to 6 months to respond to axi-cel and up to 12 months with tisagenlecleucel. That response is mostly an imaging epiphenomenon rather than a biological delay, says Andreadis. PET scans can be positive for many reasons including inflammation and T-cell infiltration, adds Andreadis. Therefore, it is important to have some signs of clinical progression or some evidence by biopsy that there is actual disease left before therapy is abandoned or changed.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.